Answers are grounded in this paper and cite their sources.
Demonstrates longer progression-free survival with nivolumab plus AVD in advanced-stage classic Hodgkin lymphoma, indicating a superior first-line regimen.
N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.).
No takes yet. Share an insight, caveat, or question.
Herrera et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: